Skip to menu Skip to content Skip to footer
Dr Sahar Keshvari
Dr

Sahar Keshvari

Email: 

Overview

Background

Dr Keshvari is a postdoctoral research officer at Mater Research Institute-UQ. Her main research interest is to investigate the role of macrophages in metabolic disorders including acute and chronic liver diseases, obesity and type 2 diabetes. She was awarded her PhD titled “characterisation of two receptors for adiponectin” in 2016 and received the “2016 Dean’s Award for Outstanding Higher Degree by Research Theses”. She is the recipient of Australian Liver Foundation fellowship and is an NHMRC Emerging Leader Investigator. Her current project is focused on the beneficial effect of macrophage colony stimulating factor on resolving liver fibrosis and promoting liver regeneration and the role of macrophages on metabolic regulation in fat and endocrine system including pancreas.

Availability

Dr Sahar Keshvari is:
Available for supervision

Works

Search Professor Sahar Keshvari’s works on UQ eSpace

40 works between 2013 and 2024

1 - 20 of 40 works

2024

Journal Article

Non-classical monocytes scavenge the growth factor CSF1 from endothelial cells in the peripheral vascular tree to ensure survival and homeostasis

Thierry, Guilhem R., Baudon, Elisa M., Bijnen, Mitchell, Bellomo, Alicia, Lagueyrie, Marine, Mondor, Isabelle, Simonnet, Louise, Carrette, Florent, Fenouil, Romain, Keshvari, Sahar, Hume, David A., Dombrowicz, David and Bajenoff, Marc (2024). Non-classical monocytes scavenge the growth factor CSF1 from endothelial cells in the peripheral vascular tree to ensure survival and homeostasis. Immunity, 57 (9), 2108-2121.e6. doi: 10.1016/j.immuni.2024.07.005

Non-classical monocytes scavenge the growth factor CSF1 from endothelial cells in the peripheral vascular tree to ensure survival and homeostasis

2024

Journal Article

Pancreatic beta-cell IL-22 receptor deficiency induces age-dependent dysregulation of insulin biosynthesis and systemic glucose homeostasis

Sajiir, Haressh, Wong, Kuan Yau, Müller, Alexandra, Keshvari, Sahar, Burr, Lucy, Aiello, Elena, Mezza, Teresa, Giaccari, Andrea, Sebastiani, Guido, Dotta, Francesco, Ramm, Grant A., Macdonald, Graeme A., McGuckin, Michael A., Prins, Johannes B. and Hasnain, Sumaira Z. (2024). Pancreatic beta-cell IL-22 receptor deficiency induces age-dependent dysregulation of insulin biosynthesis and systemic glucose homeostasis. Nature Communications, 15 (1) 4527, 1-12. doi: 10.1038/s41467-024-48320-2

Pancreatic beta-cell IL-22 receptor deficiency induces age-dependent dysregulation of insulin biosynthesis and systemic glucose homeostasis

2024

Journal Article

Liver and pancreatic-targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated steatohepatitis

Sajiir, Haressh, Keshvari, Sahar, Wong, Kuan Yau, Borg, Danielle J., Steyn, Frederik J., Fercher, Christian, Taylor, Karin, Taylor, Breten, Barnard, Ross T., Müller, Alexandra, Moniruzzaman, Md, Miller, Gregory, Wang, Ran, Fotheringham, Amelia, Schreiber, Veronika, Sheng, Yong Hua, Hancock, Janelle Louise, Loo, Dorothy, Burr, Lucy, Huynh, Tony, Lockett, Jack, Ramm, Grant A., Macdonald, Graeme A., Prins, Johannes B., McGuckin, Michael A. and Hasnain, Sumaira Z. (2024). Liver and pancreatic-targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated steatohepatitis. Nature Communications, 15 (1) 4528, 4528. doi: 10.1038/s41467-024-48317-x

Liver and pancreatic-targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated steatohepatitis

2024

Journal Article

Relative contributions of osteal macrophages and osteoclasts to postnatal bone development in CSF1R-deficient rats and phenotype rescue following wild-type bone marrow cell transfer

Batoon, Lena, Keshvari, Sahar, Irvine, Katharine M, Ho, Eileen, Caruso, Melanie, Patkar, Omkar L, Sehgal, Anuj, Millard, Susan M, Hume, David A and Pettit, Allison R (2024). Relative contributions of osteal macrophages and osteoclasts to postnatal bone development in CSF1R-deficient rats and phenotype rescue following wild-type bone marrow cell transfer. Journal of Leukocyte Biology, 116 (4), 753-765. doi: 10.1093/jleuko/qiae077

Relative contributions of osteal macrophages and osteoclasts to postnatal bone development in CSF1R-deficient rats and phenotype rescue following wild-type bone marrow cell transfer

2024

Journal Article

Reversible expansion of tissue macrophages in response to macrophage colony-stimulating factor (CSF1) transforms systemic lipid and carbohydrate metabolism

Keshvari, Sahar, Masson, Jesse J.R., Ferrari-Cestari, Michelle, Bodea, Liviu-Gabriel, Nooru-Mohamed, Fathima, Tse, Brian W.C., Sokolowski, Kamil A., Batoon, Lena, Patkar, Omkar L., Sullivan, Mitchell A., Ebersbach, Hilmar, Stutz, Cian, Parton, Robert G., Summers, Kim M., Pettit, Allison R., Hume, David A. and Irvine, Katharine M. (2024). Reversible expansion of tissue macrophages in response to macrophage colony-stimulating factor (CSF1) transforms systemic lipid and carbohydrate metabolism. American Journal of Physiology-Endocrinology and Metabolism, 326 (2), E149-E165. doi: 10.1152/ajpendo.00347.2023

Reversible expansion of tissue macrophages in response to macrophage colony-stimulating factor (CSF1) transforms systemic lipid and carbohydrate metabolism

2023

Journal Article

Macrophage deficiency in CSF1R-knockout rat embryos does not compromise placental or embryo development

Hume, David A, Teakle, Ngari, Keshvari, Sahar and Irvine, Katharine M (2023). Macrophage deficiency in CSF1R-knockout rat embryos does not compromise placental or embryo development. Journal of Leukocyte Biology, 114 (5), 421-433. doi: 10.1093/jleuko/qiad052

Macrophage deficiency in CSF1R-knockout rat embryos does not compromise placental or embryo development

2023

Journal Article

Intraperitoneal transfer of wild‐type bone marrow repopulates tissue macrophages in the Csf1r knockout rat without contributing to monocytopoiesis

Sehgal, Anuj, Carter‐Cusack, Dylan, Keshvari, Sahar, Patkar, Omkar, Huang, Stephen, Summers, Kim M., Hume, David A. and Irvine, Katharine M. (2023). Intraperitoneal transfer of wild‐type bone marrow repopulates tissue macrophages in the Csf1r knockout rat without contributing to monocytopoiesis. European Journal of Immunology, 53 (8) 2250312, e2250312. doi: 10.1002/eji.202250312

Intraperitoneal transfer of wild‐type bone marrow repopulates tissue macrophages in the Csf1r knockout rat without contributing to monocytopoiesis

2023

Conference Publication

Mechanisms underlying the rescue of postnatal bone development in CSF1R-deficient rats following wild-type bone marrow cell transfer

Batoon, Lena, Keshvari, Sahar, Irvine, Katharine, Caruso, Melanie, Patkar, Omkar, Sehgal, Anuj, Millard, Susan, Hume, David and Pettit, Allison (2023). Mechanisms underlying the rescue of postnatal bone development in CSF1R-deficient rats following wild-type bone marrow cell transfer. 2022 Annual Meeting of the American Society for Bone and Mineral Research, Austin, TX, United States, 9-12 September 2022. Hoboken, NJ, United States: Wiley-Blackwell.

Mechanisms underlying the rescue of postnatal bone development in CSF1R-deficient rats following wild-type bone marrow cell transfer

2023

Journal Article

Serum CCL2 is associated with visceral adiposity but not fibrosis in patients with Non-alcoholic Fatty Liver Disease (NAFLD)

Ferrari-Cestari, Michelle, Okano, Satomi, Patel, Preya J., Horsfall, Leigh U., Keshvari, Sahar, Hume, David A., Williams, Suzanne, Russell, Anthony, Powell, Elizabeth E. and Irvine, Katharine M (2023). Serum CCL2 is associated with visceral adiposity but not fibrosis in patients with Non-alcoholic Fatty Liver Disease (NAFLD). Digestive Diseases, 41 (3), 439-446. doi: 10.1159/000527784

Serum CCL2 is associated with visceral adiposity but not fibrosis in patients with Non-alcoholic Fatty Liver Disease (NAFLD)

2023

Journal Article

Fibrillin-1 and asprosin, novel players in metabolic syndrome

Summers, Kim M., Bush, Stephen J., Davis, Margaret R., Hume, David A., Keshvari, Sahar and West, Jennifer A. (2023). Fibrillin-1 and asprosin, novel players in metabolic syndrome. Molecular Genetics and Metabolism, 138 (1) 106979, 106979. doi: 10.1016/j.ymgme.2022.106979

Fibrillin-1 and asprosin, novel players in metabolic syndrome

2022

Journal Article

CSF1R as a therapeutic target in bone diseases: obvious but not so simple

Hume, David A., Batoon, Lena, Sehgal, Anuj, Keshvari, Sahar and Irvine, Katharine M. (2022). CSF1R as a therapeutic target in bone diseases: obvious but not so simple. Current Osteoporosis Reports, 20 (6), 516-531. doi: 10.1007/s11914-022-00757-4

CSF1R as a therapeutic target in bone diseases: obvious but not so simple

2022

Journal Article

Building a case for pancreas and liver targeted intereukin-22 therapy in fatty liver disease

Sajiir, Haressh, Wong, Kuan Yau, Mueller, Alexandra, Keshvari, Sahar, Wang, Ran, Wiid, Percival, Ramm, Grant, Macdonald, Graeme, Prins, John, McGuckin, Michael and Hasnain, Sumaira (2022). Building a case for pancreas and liver targeted intereukin-22 therapy in fatty liver disease. Journal of Hepatology, 77 (Supplement 1), S190-S191. doi: 10.1016/s0168-8278(22)00756-5

Building a case for pancreas and liver targeted intereukin-22 therapy in fatty liver disease

2022

Conference Publication

Targeted IL-22 Improves Glucose Tolerance and Reduces Hepatic Steatosis and Hepatic Fibrosis in Murine Models of Diabetes and Liver Disease

Prins, John B., Sajiir, Haressh, Keshvari, Sahar, Wong, Kuan Yau, Lockett, Jack, McGuckin, Michael and Hasnain, Sumaira Z. (2022). Targeted IL-22 Improves Glucose Tolerance and Reduces Hepatic Steatosis and Hepatic Fibrosis in Murine Models of Diabetes and Liver Disease. American Diabetes Association 82nd Scientific Sessions, New Orleans, LA United States, 3-7 June 2021. Arlington, VA United States: American Diabetes Association. doi: 10.2337/db22-119-lb

Targeted IL-22 Improves Glucose Tolerance and Reduces Hepatic Steatosis and Hepatic Fibrosis in Murine Models of Diabetes and Liver Disease

2022

Conference Publication

Building a case for liver and pancreas targeted interleukin-22 therapy for use in non-alcoholic fatty liver disease

Sajiir, Haressh, Wong, Kuanyau, Mueller, Alexander, Keshvari, Sahar, Wang, Ran, Macdonald, Graeme A., Prins, John, Mcguckin, Michael and Hasnain, Sumaira Z. (2022). Building a case for liver and pancreas targeted interleukin-22 therapy for use in non-alcoholic fatty liver disease. Digestive Disease Week 2022, San Diego, CA United States, 21-24 May 2022. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(22)60035-0

Building a case for liver and pancreas targeted interleukin-22 therapy for use in non-alcoholic fatty liver disease

2022

Conference Publication

Pancreatic Interleukin-22 Receptor Signaling is Critical in Maintaining Beta-Cell Insulin Production and is Hepatoprotective

Sajiir, Haressh, Wong, Kuan Yau, Mueller, Alexandra, Keshvari, Sahar, Wang, Ran, Wiid, Percival, Macdonald, Graeme, Prins, John, McGuckin, Michael A. and Hasnain, Sumaira Z. (2022). Pancreatic Interleukin-22 Receptor Signaling is Critical in Maintaining Beta-Cell Insulin Production and is Hepatoprotective. Immunology 2022 Meeting, Portland, OR United States, 6-10 May 2022. Rockville, MD United States: American Association of Immunologists. doi: 10.4049/jimmunol.208.supp.46.08

Pancreatic Interleukin-22 Receptor Signaling is Critical in Maintaining Beta-Cell Insulin Production and is Hepatoprotective

2022

Journal Article

Editorial: Adipose Tissue in Obesity and Metabolic Disease

Keshvari, Sahar, Ceddia, Ryan P., Rajbhandari, Prashant, Chaurasia, Bhagirath and Bond, Simon T. (2022). Editorial: Adipose Tissue in Obesity and Metabolic Disease. Frontiers in Physiology, 13 898861. doi: 10.3389/fphys.2022.898861

Editorial: Adipose Tissue in Obesity and Metabolic Disease

2022

Journal Article

A kinase-dead Csf1r mutation associated with adult-onset leukoencephalopathy has a dominant inhibitory impact on CSF1R signalling

Stables, Jennifer, Green, Emma K., Sehgal, Anuj, Patkar, Omkar L., Keshvari, Sahar, Taylor, Isis, Ashcroft, Maisie E., Grabert, Kathleen, Wollscheid-Lengeling, Evi, Szymkowiak, Stefan, McColl, Barry W., Adamson, Antony, Humphreys, Neil E., Mueller, Werner, Starobova, Hana, Vetter, Irina, Shabestari, Sepideh Kiani, Blurton-Jones, Matthew M., Summers, Kim M., Irvine, Katharine M., Pridans, Clare and Hume, David A. (2022). A kinase-dead Csf1r mutation associated with adult-onset leukoencephalopathy has a dominant inhibitory impact on CSF1R signalling. Development, 149 (8) dev200237. doi: 10.1242/dev.200237

A kinase-dead Csf1r mutation associated with adult-onset leukoencephalopathy has a dominant inhibitory impact on CSF1R signalling

2022

Other Outputs

Glucocorticoid activity regulates glucocorticoid receptor isoform expression and downstream gene transcription in humans

Lockett, Jack , Saif, Zarqa, Nolan, Brendan J., Keshvari, Sahar, Cesana-Nigro, Nicole, Ewing, Adam, Inder, Warrick J. and Clifton, Vicki L. (2022). Glucocorticoid activity regulates glucocorticoid receptor isoform expression and downstream gene transcription in humans. The University of Queensland. (Dataset) doi: 10.48610/ee0c38e

Glucocorticoid activity regulates glucocorticoid receptor isoform expression and downstream gene transcription in humans

2022

Journal Article

Therapeutic potential of macrophage colony-stimulating factor (CSF1) in chronic liver disease

Keshvari, Sahar, Genz, Berit, Teakle, Ngari, Caruso, Melanie, Cestari, Michelle F., Patkar, Omkar L., Tse, Brian W. C., Sokolowski, Kamil A., Ebersbach, Hilmar, Jascur, Julia, MacDonald, Kelli P. A., Miller, Gregory, Ramm, Grant A., Pettit, Allison R., Clouston, Andrew D., Powell, Elizabeth E., Hume, David A. and Irvine, Katharine M. (2022). Therapeutic potential of macrophage colony-stimulating factor (CSF1) in chronic liver disease. Disease Models and Mechanisms, 15 (4) dmm049387, 1-15. doi: 10.1242/dmm.049387

Therapeutic potential of macrophage colony-stimulating factor (CSF1) in chronic liver disease

2021

Journal Article

Pre-Diabetes Increases Tuberculosis Disease Severity, While High Body Fat Without Impaired Glucose Tolerance Is Protective

Sinha, Roma, Ngo, Minh Dao, Bartlett, Stacey, Bielefeldt-Ohmann, Helle, Keshvari, Sahar, Hasnain, Sumaira Z., Donovan, Meg L., Kling, Jessica C., Blumenthal, Antje, Chen, Chen, Short, Kirsty R. and Ronacher, Katharina (2021). Pre-Diabetes Increases Tuberculosis Disease Severity, While High Body Fat Without Impaired Glucose Tolerance Is Protective. Frontiers in Cellular and Infection Microbiology, 11 691823, 691823. doi: 10.3389/fcimb.2021.691823

Pre-Diabetes Increases Tuberculosis Disease Severity, While High Body Fat Without Impaired Glucose Tolerance Is Protective

Funding

Current funding

  • 2025 - 2029
    Macrophage Therapeutic Potential in Paediatric Non-Alcoholic Fatty Liver Disease
    NHMRC Investigator Grants
    Open grant
  • 2022 - 2024
    Macrophage-driven lipid metabolism in health and disease - mechanisms and therapeutic opportunities
    NHMRC IDEAS Grants
    Open grant
  • 2022 - 2024
    Therapeutic Application of Macrophage Colony Stimulating Factor (CSF1) for Liver Regeneration
    Liver Foundation Pauline Hall PostDoc Research Fellowship
    Open grant

Past funding

  • 2018 - 2019
    Development of an IL-22 based immunocytokine as a novel therapeutic approach in type 2 diabetes
    Diabetes Australia Research Trust
    Open grant

Supervision

Availability

Dr Sahar Keshvari is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Available projects

  • Macrophage Therapeutic Potential in Paediatric Non-alcoholic Fatty Liver Disease

    Metabolic diseases, including obesity and its associated spectrum of pathologies, represent some the greatest health challenges we currently face. Macrophages, cells of the innate immune system, regulate many aspects of metabolism in health and disease. They form abundant resident populations in major metabolic tissues such as liver and fat, where they regulate energy homeostasis and prevent inflammation. But recruited or activated macrophages contribute to inflammation-driven metabolic maladaptation that is central to the development of metabolic diseases, including obesity, type 2 diabetes, and non-alcoholic fatty liver disease. We have discovered that stimulating macrophages can induce liver growth and alter body composition – promoting increased lean mass, reduced fat mass and reduced liver fat. We hypothesise that macrophages are a component of the regulatory network that controls metabolic homeostasis, which has clear therapeutic implications for obesity and related pathologies. The proposed project forms part of the NHMRC Investigator Grant “Macrophage Therapeutic Potential in Paediatric Non-alcoholic Fatty Liver Disease”. The aim of the project is to understand the role of the innate immune system in childhood obesity and fatty liver disease.

Supervision history

Current supervision

Completed supervision

Media

Enquiries

For media enquiries about Dr Sahar Keshvari's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au